Two Sigma Advisers
BIO icon

Two Sigma Advisers’s Bio-Rad Laboratories Class A BIO Stock Holding History

Two Sigma Advisers’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,100
Closed -$2.76M – 283
2025
Q4 		$2.76M Sell
9,100
-400
-4% -$125K 0.01% 1060
2025
Q3 		$2.66M Buy
9,500
+500
+6% +$136K 0.01% 1001
2025
Q2 		$2.17M Sell
9,000
-600
-6% -$142K ﹤0.01% 1083
2025
Q1 		$2.34M Sell
9,600
-500
-5% -$150K 0.01% 1096
2024
Q4 		$3.32M Sell
10,100
-800
-7% -$272K 0.01% 887
2024
Q3 		$3.65M Sell
10,900
-3,968
-27% -$1.26M 0.01% 821
2024
Q2 		$4.06M Sell
14,868
-2,300
-13% -$669K 0.01% 858
2024
Q1 		$5.94M Sell
17,168
-3,800
-18% -$1.25M 0.01% 711
2023
Q4 		$6.77M Sell
20,968
-31,800
-60% -$9.97M 0.02% 687
2023
Q3 		$18.9M Buy
52,768
+700
+1% +$270K 0.05% 323
2023
Q2 		$19.7M Buy
52,068
+3,200
+7% +$1.3M 0.05% 308
2023
Q1 		$23.4M Sell
48,868
-14,400
-23% -$6.74M 0.06% 288
2022
Q4 		$26.6M Buy
63,268
+11,200
+22% +$4.52M 0.07% 260
2022
Q3 		$21.7M Buy
52,068
+6,900
+15% +$3.44M 0.06% 303
2022
Q2 		$22.4M Buy
45,168
+9,800
+28% +$5.1M 0.06% 301
2022
Q1 		$19.9M Buy
35,368
+18,600
+111% +$11.2M 0.05% 322
2021
Q4 		$12.7M Buy
16,768
+15,200
+969% +$11.4M 0.03% 432
2021
Q3 		$1.17M Buy
1,568
+1,200
+326% +$899K ﹤0.01% 1543
2021
Q2 		$237K Sell
368
-500
-58% -$304K ﹤0.01% 2223
2021
Q1 		$496K Buy
+868
New +$514K ﹤0.01% 2016
2020
Q3 		– Sell
-20,765
Closed -$9.38M – 2407
2020
Q2 		$9.38M Sell
20,765
-29,200
-58% -$12.9M 0.03% 579
2020
Q1 		$17.5M Sell
49,965
-50,500
-50% -$18.6M 0.07% 315
2019
Q4 		$37.2M Buy
100,465
+1,300
+1% +$458K 0.09% 259
2019
Q3 		$33M Buy
99,165
+33,900
+52% +$11.1M 0.08% 281
2019
Q2 		$20.4M Sell
65,265
-5,100
-7% -$1.53M 0.05% 397
2019
Q1 		$21.5M Buy
70,365
+62,500
+795% +$16.9M 0.05% 393
2018
Q4 		$1.83M Sell
7,865
-2,900
-27% -$778K 0.01% 1211
2018
Q3 		$3.37M Buy
10,765
+700
+7% +$217K 0.01% 992
2018
Q2 		$2.9M Buy
10,065
+1,500
+18% +$414K 0.01% 1125
2018
Q1 		$2.14M Sell
8,565
-13,800
-62% -$3.51M 0.01% 1218
2017
Q4 		$5.34M Buy
22,365
+18,800
+527% +$4.56M 0.01% 824
2017
Q3 		$792K Buy
3,565
+2,200
+161% +$495K ﹤0.01% 1564
2017
Q2 		$309K Sell
1,365
-1,000
-42% -$218K ﹤0.01% 1982
2017
Q1 		$471K Sell
2,365
-800
-25% -$154K ﹤0.01% 1922
2016
Q4 		$577K Sell
3,165
-1,200
-27% -$205K ﹤0.01% 1798
2016
Q3 		$715K Sell
4,365
-5,200
-54% -$789K ﹤0.01% 1506
2016
Q2 		$1.37M Sell
9,565
-25,500
-73% -$3.64M 0.01% 1022
2016
Q1 		$4.79M Sell
35,065
-2,700
-7% -$354K 0.03% 513
2015
Q4 		$5.24M Sell
37,765
-28,100
-43% -$3.89M 0.03% 435
2015
Q3 		$8.87M Sell
65,865
-17,200
-21% -$2.48M 0.06% 353
2015
Q2 		$12.5M Buy
83,065
+800
+1% +$114K 0.09% 252
2015
Q1 		$11.1M Buy
82,265
+57,800
+236% +$7.16M 0.08% 290
2014
Q4 		$2.95M Buy
24,465
+1,000
+4% +$115K 0.02% 669
2014
Q3 		$2.66M Sell
23,465
-6,300
-21% -$746K 0.02% 714
2014
Q2 		$3.56M Buy
29,765
+21,200
+248% +$2.59M 0.03% 576
2014
Q1 		$1.1M Sell
8,565
-700
-8% -$89.7K 0.01% 1106
2013
Q4 		$1.15M Sell
9,265
-12,200
-57% -$1.49M 0.01% 1060
2013
Q3 		$2.52M Sell
21,465
-13,083
-38% -$1.54M 0.03% 537
2013
Q2 		$3.88M Buy
+34,548
New +$4.05M 0.06% 305

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers's BIO Position: Q1 2026 in Review

Two Sigma Advisers sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 9,100 shares — an estimated $2.76M sold.

Two Sigma Advisers first reported a position in BIO in Q2 2013 and held it in 49 quarters. The position peaked at $37.2M in Q4 2019. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Two Sigma Advisers reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 9,100 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $2.76M.
  • Two Sigma Advisers first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 49 quarters.
  • Two Sigma Advisers's Bio-Rad Laboratories Class A position peaked at $37.2M in Q4 2019.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.